Gritstone bio (GRTS)
(Delayed Data from NSDQ)
$0.48 USD
+0.02 (5.44%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $0.48 0.00 (0.67%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Brokerage Reports
Gritstone bio Inc. [GRTS]
Reports for Purchase
Showing records 21 - 37 ( 37 total )
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
Expanding Clinical Pipeline with Multiple Readouts in 2021; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
COVID Program Could Bring Near-Term Upside; Higher $24 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
Phase 2 Initiated With Four Clinical Readouts in 2021; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
Advancing to Phase 2 With Results Expected in 2021; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
Encouraging Data Update on GRANITE and SLATE; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
Clinical Programs Remain on Track Despite Pandemic; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
Market Shudders But We See Names to Outperform.
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
Phase 2 Studies of SLATE and GRANITE Could Initiate in 2H20; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
Encouraging First Look on SLATE; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
Promising Initial Clinical Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
Major Clinical Update Coming in December; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
Closer Look at SLATE at SITC; What to Expect at ESMO IO; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
First Clinical Results Expected in Q4; Adjusting PT to $16; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
First Looks at GRANITE and SLATE in Q4; Bispecific Candidate Before YE; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
AACR Presentations Highlight EDGE Advantages; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
Clinical Programs On-Track; New Insights Into EDGE at AACR; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Gritstone bio Inc.
Industry: Medical - Biomedical and Genetics
The Leading EDGE of Neoantigen-Targeting Therapies; Initiate With a Buy and $17.00 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S